Lakdawalla and Malani Author Two-Part Series on ACA in The Conversation
In a new two-part series featured in The Conversation, PHE’s Darius Lakdawalla and co-author Anup Malani provide an ACA primer, as well as look at the landscape of health care reform going forward.
In Part One, Lakdawalla and Malani examine the provisions of the Affordable Care Act, focusing on three of its most important elements.
In Part Two, they offer a proposal of specific recommendations designed to provide a roadmap for Congress’ planned repeal and replacement of the ACA.
To read Part One, please click here.
To read Part Two, please click here.
By: Jason Shafrin, PhD Sr. Director, Policy and Economics and Jacki Chou, MPL Senior Director, Policy and Economics The recent announcement that CVS Caremark will use value-based metrics to inform formulary design at first appears a step in the right direction. However, using value measurements from a single nongovernmental organization—the Institute for Clinical and Economic Review (ICER)—based on a limited picture of treatment value may be problematic. Using this single assessment of value in an effort solely to exclude drugs from a major insurance formulary is even more worrisome and fails to recognize the heterogeneity in patient clinical needs and preferences.